FDA Removes Clinical Hold on Phase I/II Study of Angelman Syndrome Treatment

GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that FDA has removed the clinical hold on GTX-102, an investigational treatment for Angelman syndrome.